On Monday, Shares of Las Vegas Sands Corp. (NYSE:LVS), gained 2.23% to $50.62.
Multi-platinum GRAMMY-nominated singer and songwriter Carly Rae Jepsen will ring in the New Year at Venetian Las Vegas during three concert performances: Dec. 30, and 31, 2015 and Jan. 2, 2016. Jepsen will perform her headline shows inside The Venetian Theatre.
Las Vegas Sands Corp. develops, owns, and operates integrated resorts in Asia and the United States. The company owns and operates The Venetian Macao Resort Hotel, Sands Cotai Central, the Four Seasons Hotel Macao, the Plaza Casino, and the Sands Macao in Macau, the People’s Republic of China.
Shares of Allergan PLC (NYSE:AGN), inclined 2.10% to $314.96, during its last trading session.
Ironwood Pharmaceuticals, and Allergan plc (AGN), declared the initiation of a Phase IIb clinical trial evaluating two orally-administered colonic release formulations of linaclotide in adult patients with irritable bowel syndrome with constipation (IBS-C). The two formulations are being evaluated together in this trial to support potential advancement of two distinct product opportunities into late stage development, one for patients with IBS-C who suffer from both abdominal pain and constipation symptoms, and the other for patients suffering from other gastrointestinal (GI) disorders with lower abdominal pain as a predominant symptom. Data from the Phase IIb clinical trial in IBS-C are predictable in the second half of 2016.
Linaclotide is the first and only FDA-approved guanylate cyclase‐C (GC‐C) agonist; it is approved as a 145 mcg capsule to be taken once per day for the treatment of adults with chronic idiopathic constipation (CIC) and as a 290 mcg capsule to be taken once per day for the treatment of adults with IBS-C. Linaclotide binds to the GC-C receptor in the intestine and is thought to work in two ways, based on non-clinical studies: by decreasing the activity of pain-sensing nerves and by increasing fluid secretion into the intestine. The investigational linaclotide colonic release formulations are designed to provide targeted delivery of linaclotide to the distal small intestine and colon, and the companies believe this may further decrease the activity of key pain-sensing nerves in the colon with a smaller improvement in fluid secretion.
“Abdominal pain is a key symptom of many gastrointestinal diseases, counting IBS-C. Millions of patients are influenced by abdominal pain, and they have few prescription options,” said David Nicholson, Ph.D., executive vice president of brand research and development at Allergan. “Our aim in this trial is to evaluate the potential of our two linaclotide colonic release formulations to provide improved abdominal pain relief to patients suffering from IBS-C in addition to to evaluate the differences between the two formulations and inform a path forward for developing a drug that can reduce gastrointestinal pain in other disorders, such as other types of IBS, ulcerative colitis and diverticulitis.”
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution.
Finally, Shares of Mastercard Inc (NYSE:MA), ended its last trade with 0.39% gain, and closed at $99.38.
MasterCard, declared its participation in the following investor conferences in the month of November:
On Tuesday, November 10, Ed McLaughlin, chief emerging payments officer, will present at the Citi Financial Technology Conference in New York. The negotiation will start at 8:40 a.m. Eastern Time and last for about 35 minutes.
On Wednesday, November 11, Chris McWilton, president, North America, will present at the RBC Capital Markets’ Technology, Media and Telecommunications Conference in New York. The negotiation will start at 10:20 a.m. Eastern Time and last for about 25 minutes.
MasterCard Incorporated, a technology company, provides transaction processing and other payment-related products and services in the United States and internationally. The company facilitates the processing of payment transactions, counting authorization, clearing, and settlement, in addition to delivers related products and services.